FDA approves Foundayo (orforglipron), an oral GLP-1 pill for obesity, under a national priority voucher

Eli Lilly/Orforglipron (Foundayo)

The FDA approved Foundayo (orforglipron), a GLP-1 pill for adults with obesity or overweight with weight-related medical problems. It can be taken at any time of day without food or water restrictions. Adults on the top dose lost an average of 27 pounds in the ATTAIN-1 trial, with pricing assistance available starting at $25 per month with a Lilly discount card.

• Oral GLP-1 agonist; can be taken without food or water restrictions, any time of day
• ATTAIN-1 trial: adults on top dose lost average 27 pounds
• Improvements in waist circumference, blood pressure, triglycerides, cholesterol
• FDA approval under priority voucher; pricing $25/month with discount card, $149–$349 for cash payers by dose